Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $80.00

Dianthus Therapeutics (NASDAQ:DNTH) had its target price hoisted by analysts at Wedbush from $55.00 to $80.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 0.97% from the company’s current price.

Several other research analysts have also recently commented on the stock. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday. Robert W. Baird increased their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Finally, Truist Financial increased their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $115.33.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $79.23 on Tuesday. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $84.86. The firm’s 50 day moving average price is $49.17 and its 200-day moving average price is $41.17. The firm has a market cap of $3.42 billion, a P/E ratio of -22.77 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $43,000. Seven Fleet Capital Management LP acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at about $604,000. Invesco Ltd. raised its position in Dianthus Therapeutics by 125.9% during the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock worth $4,182,000 after acquiring an additional 56,560 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $550,000. Finally, Voloridge Investment Management LLC grew its position in shares of Dianthus Therapeutics by 80.5% in the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock valued at $1,627,000 after purchasing an additional 17,612 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.